Nyxoah Showcases Commercial Progress of Genio System in the United States
On Wednesday, Nyxoah participated in an exclusive event at LégiaPark, the life sciences innovation campus located in Liège, bringing together around forty investors and press representatives. The medical technology company presented the commercial progress of the Genio system in the United States, less than a year after its FDA approval.
Commercial Progress of the Genio System in the United States
Olivier Taelman, CEO of Nyxoah, detailed to attendees the commercial advancements of the Genio system in the United States since its FDA approval in August 2025. He also discussed the company's recently announced investment in LégiaPark, a large-scale production site aimed at expanding industrial capacity in line with Nyxoah's growth ambitions.
The Genio system is a probeless and batteryless hypoglossal nerve neurostimulation therapy designed to treat obstructive sleep apnea syndrome (OSAS), the most common sleep-related breathing disorder. The device received CE marking in 2019 and FDA approval in August 2025.
LégiaPark, a Reference Cluster in Wallonia
Located on the heights of Liège, LégiaPark is described as a reference life sciences cluster in Wallonia. The campus now hosts two publicly traded Belgian companies, Nyxoah and Hyloris Pharmaceuticals, on the same site. Hyloris also participated in the event, presenting its strategy and portfolio of innovative drugs under development to visitors.
